BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Article 2014 en
Authors
HR
Helen Rizos
AM
Alexander M. Menzies
GP
Gulietta M. Pupo
Abstract
1 min read
Selecting sequential drugs based on the molecular characteristics of a single progressing biopsy is unlikely to provide improved responses, and first-line therapies targeting multiple pathways will be required.
Helen Rizos, Alexander M. Menzies, Gulietta M. Pupo, Matteo S. Carlino, Carina Fung, Jessica Hyman, Lauren E. Haydu, Branka Mijatov, Therese M. Becker, Suzanah C. Boyd, Julie R. Howle, Robyn P.M. Saw, John F. Thompson, Richard F. Kefford, Richard A Scolyer, Georgina V. Long
Helen Rizos, Alexander M. Menzies, Gulietta M. Pupo, Matteo S. Carlino, Carina Fung, Jessica Hyman, Lauren E. Haydu, Branka Mijatov, Therese M. Becker, Suzanah C. Boyd, Julie R. Howle, Robyn P.M. Saw, John F. Thompson, Richard F. Kefford, Richard A Scolyer, Georgina V. Long
Helen Rizos, Alexander M. Menzies, Gulietta M. Pupo, Matteo S. Carlino, Carina Fung, Jessica Hyman, Lauren E. Haydu, Branka Mijatov, Therese M. Becker, Suzanah C. Boyd, Julie R. Howle, Robyn P.M. Saw, John F. Thompson, Richard F. Kefford, Richard A Scolyer, Georgina V. Long
Helen Rizos, Alexander M. Menzies, Gulietta M. Pupo, Matteo S. Carlino, Carina Fung, Jessica Hyman, Lauren E. Haydu, Branka Mijatov, Therese M. Becker, Suzanah C. Boyd, Julie R. Howle, Robyn P.M. Saw, John F. Thompson, Richard F. Kefford, Richard A Scolyer, Georgina V. Long
James S. Wilmott, Varsha Tembe, Julie R. Howle, Raghwa Sharma, John F. Thompson, Helen Rizos, Roger S. Lo, Richard Kefford, Richard A Scolyer, Georgina V. Long
Discussion(0)
No comments yet. Be the first to comment.